| Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM P Moreau, A Chanan-Khan, AW Roberts, AB Agarwal, T Facon, S Kumar, ... Blood, The Journal of the American Society of Hematology 130 (22), 2392-2400, 2017 | 285 | 2017 |
| Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-Hodgkin lymphomas JW Friedberg, D Mahadevan, E Cebula, D Persky, I Lossos, AB Agarwal, ... Journal of Clinical Oncology 32 (1), 44, 2014 | 245 | 2014 |
| Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and … A Agarwal, IM Ghobrial Clinical Cancer Research 19 (5), 985-994, 2013 | 115 | 2013 |
| Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment DS Siegel, GJ Schiller, C Samaras, M Sebag, J Berdeja, S Ganguly, ... Leukemia 34 (12), 3286-3297, 2020 | 79 | 2020 |
| American Society of Clinical Oncology strategic plan for increasing racial and ethnic diversity in the oncology workforce KM Winkfield, CR Flowers, JD Patel, G Rodriguez, P Robinson, A Agarwal, ... AMER SOC CLINICAL ONCOLOGY, 2017 | 62 | 2017 |
| Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines … W Qi, C Spier, X Liu, A Agarwal, LS Cooke, DO Persky, D Chen, TP Miller, ... Leukemia research 37 (4), 434-439, 2013 | 62 | 2013 |
| KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma S Jagannath, Y Lin, H Goldschmidt, D Reece, A Nooka, A Senin, ... Blood cancer journal 11 (6), 116, 2021 | 59 | 2021 |
| Denosumab chemotherapy for recurrent giant-cell tumor of bone: a case report of neoadjuvant use enabling complete surgical resection A Agarwal, BT Larsen, LD Buadu, J Dunn, R Crawford, J Daniel, ... Case reports in oncological medicine 2013, 2013 | 57 | 2013 |
| Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure DS Siegel, GJ Schiller, KW Song, R Agajanian, K Stockerl‐Goldstein, ... British journal of haematology 188 (4), 501-510, 2020 | 50 | 2020 |
| Developing next generation immunomodulatory drugs and their combinations in multiple myeloma A Thakurta, WE Pierceall, MD Amatangelo, E Flynt, A Agarwal Oncotarget 12 (15), 1555, 2021 | 36 | 2021 |
| Minimal residual disease in myeloma: application for clinical care and new drug registration KC Anderson, D Auclair, SJ Adam, A Agarwal, M Anderson, ... Clinical Cancer Research 27 (19), 5195-5212, 2021 | 34 | 2021 |
| Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM S Jagannath, R Abonour, BGM Durie, M Narang, HR Terebelo, ... Blood advances 2 (13), 1608-1615, 2018 | 33 | 2018 |
| Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016) S Jagannath, R Abonour, BGM Durie, C Gasparetto, JW Hardin, ... Clinical Lymphoma Myeloma and Leukemia 18 (7), 480-485. e3, 2018 | 31 | 2018 |
| Immunomodulation in pomalidomide, dexamethasone, and daratumumab-treated patients with relapsed/refractory multiple myeloma WE Pierceall, MD Amatangelo, NJ Bahlis, DS Siegel, A Rahman, ... Clinical Cancer Research 26 (22), 5895-5902, 2020 | 30 | 2020 |
| Venetoclax combined with bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma P Moreau, AA Chanan-Khan, AW Roberts, AB Agarwal, T Facon, S Kumar, ... Blood 128 (22), 975, 2016 | 29 | 2016 |
| Safety and efficacy of venetoclax (ABT-199/GDC-0199) in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma: phase 1b results P Moreau, A Chanan-Khan, AW Roberts, AB Agarwal, T Facon, S Kumar, ... Blood 126 (23), 3038, 2015 | 25 | 2015 |
| Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study NS Raje, DS Siegel, S Jagannath, S Lonial, NC Munshi, P Moreau, ... Blood 136, 37-38, 2020 | 23 | 2020 |
| KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa. S Jagannath, Y Lin, H Goldschmidt, DE Reece, AK Nooka, ... Journal of Clinical Oncology 38 (15_suppl), 8525-8525, 2020 | 23 | 2020 |
| Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis S Ailawadhi, S Jagannath, HC Lee, M Narang, RM Rifkin, HR Terebelo, ... Cancer 126 (19), 4332-4340, 2020 | 22 | 2020 |
| Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry HR Terebelo, R Abonour, CJ Gasparetto, K Toomey, BGM Durie, ... British Journal of Haematology 187 (5), 602-614, 2019 | 19 | 2019 |
